Optimizing Dosing of Colistin for Infections Resistant to all Other Antibiotics

niversity of Athens, Medical School0 个研究点目标入组 238 人开始时间: 2010年8月17日最近更新: 2015年7月10日

适应症

试验速览

暂无简介。

•1.Patient of 18 years of age or older
•2.Expectation of hospitalization of = 48 hours
•3.Receipt of intravenous colistin for clinical care
•4.Provision of written informed consent by the patient or by a relative legally able to give proxy consent if the patient cannot give consent
•5.Infection is defined by Center for Disease Control and Prevention (CDC) definitions of bloodstream infection (bacteremia) or hospital-acquired pneumonia:85
•6.Patient must have growth from blood culture or a respiratory specimen culture of a Gram-negative bacillus lacking susceptibility to all of the following antibiotics: cefepime OR ceftazidime, imipenem OR meropenem, piperacillin/tazobactam, ciprofloxacin OR levofloxacin
•7.Adequate venous access to enable collection of blood for determination of CMS and generated colistin in plasma
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.Currently pregnant or breastfeeding
•2.Currently incarcerated
•3.Concomitant use of colistin or polymyxin B delivered directly into the respiratory tract
•4.Known allergy to colistin or polymyxin B
•5.Cystic fibrosis
•6.Estimated life expectancy of less than one week

发起方

niversity of Athens, Medical School